Skip to main navigation
Close
Main navigation
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Legislation
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
Resources
All Resources
2022 Savings Report
2022 Interactive State Savings Map
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action
Menu
Interactive Savings Map
- Find out how much your state saved from generic and biosimilar medicines.
Learn More
Close
Breadcrumb
Association for Accessible Medicines
Resources
Resources
Share
Find up-to-date information on generics and biosimilars
Filter Resources
Issues
Biosimilar User Fee Act (BsUFA)
Biosimilars
Complex Generics
Drug Approval Process (GDUFA)
Drug Prices
Drug Shortages
Generic Drug Labeling
Generic Supply Chain
IP Issues
Low Income Subsidies (LIS in Part D)
Medicaid
Medicare
NAFTA
Patent Reform
Patient Stories
Pharmaceutical Waste Take Back
Preventing Drug Abuse
Quality
REMS/Sample Acquisition Remedies
State Initiatives
Tariffs
Trade
Transparency
User Fees
Resource Type
Blog
Amicus Brief
Press Release
Infographic
Video
Report
Fact Sheet
Presentation
Report
Sep 21, 2022
| Erica Klinger
Report: 2022 U.S. Generic and Biosimilar Medicines Savings Report
Report
Jun 13, 2022
| Erica Klinger
AAM Code of Business Ethics
Report
Feb 10, 2022
| Dan Leonard
AAM Voices of Access 2022
Report
Oct 12, 2021
| Erica Klinger
Report: 2021 U.S. Generic and Biosimilar Medicines Savings Report
Report
Jul 13, 2021
| Erica Klinger
New Evidence Shows Medicare Part D Plans Continue to Fail to Get New Generics to Seniors
Report
May 24, 2021
| Erica Klinger
AAM Voices of Access
Report
Feb 22, 2021
| Erica Klinger
Roadmaps for Ensuring Patient Access to Generic and Biosimilar Medicines: Securing Sustainable Markets
Report
Feb 9, 2021
| Erica Klinger
White Paper: Potential Savings from Accelerating U.S. Approval of Complex Generics
Report
Oct 6, 2020
| Erica Klinger
White Paper: Nitrosamines — An Industry Position Paper Based on Risk
Report
Sep 29, 2020
| Erica Klinger
2020 Generic Drug & Biosimilars Access and Savings in the U.S. Report
Report
Apr 30, 2020
| Erica Klinger
A Blueprint for Enhancing the Security of the U.S. Pharmaceutical Supply Chain
Report
Feb 20, 2020
| Craig Burton
White Paper: Medicare and Commercial Plans Fail to Get New Generics to Patients
Load More
Advocacy
Issue Overview
#Rx4StateSavings
#4GRxANTED
#MarkupMadness
State Legislation
GDUFA/BsUFA User Fees
Biosimilars Council
Action Center
Our Impact
Join
About Us
Generic Quality
About AAM
Our Team
Our Members
Generic Medicines
Biosimilars Council
Meet Our Board
Social Commitment
Careers
Contact Us
Stories
Events
GRx+Biosims 2022
Access! 2022
Resources
All Resources
2022 Savings Report
2022 Interactive State Savings Map
Supply Chain Blueprint
Biosimilars Patient Resource Center
Biosimilar Research & Studies
Press Releases
Blog
Founders Blogs
Amicus Briefs
Take Action